Axosef

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Axosef: instructions for use and reviews

1. Release form and composition
2. Pharmacological properties
3. Indications for use
4. Contraindications
5. Method of application and dosage
6. Side effects
7. Overdose
8. Special instructions
9. Application during pregnancy and lactation
10. Use in childhood
11. In case of impaired renal function
12. Drug interactions
13. Analogs
14. Terms and conditions of storage
15. Terms of dispensing from pharmacies
16. Reviews
17. Price in pharmacies

Latin name: Aksosef

ATX code: J01DC02

Active ingredient: cefuroxime (Cefuroxime)

Manufacturer: Nobel Almaty Pharmaceutical Factory, JSC (Republic of Kazakhstan); Pharmavision San. Ve Tik. A. Sh. (Pharmavision San. Ve Tic. AS) (Turkey); Nobel Ilach Sanayi ve Tijaret A. Sh. (Nobel Ilac Sanayii Ve Ticaret AS) (Turkey)

Description and photo updated: 30.11.2018

Prices in pharmacies: from 119 rubles.

Buy

Axosef is an antibacterial drug for oral and parenteral use, a second generation cephalosporin.

Release form and composition

Dosage forms:

powder for preparation of a solution for intravenous (i / v) and intramuscular (i / m) administration: a loose mass of white or almost white color, has a slight hygroscopicity [250 mg or 750 mg in sterile glass pyrogen-free vials without color, in a cardboard box 1 bottle complete with one ampoule of solvent (clear liquid, colorless and odorless - 2 ml or 6 ml)];
film-coated tablets: white, oblong, flat-cylindrical, on one side there is an inscription NOBEL, on the other - a dividing line (in blisters of 7 pcs., in a cardboard box of 1 or 2 blisters; in blisters of 10 pcs., in a cardboard box) pack 1 blister).

Each pack also contains instructions for the use of Axosef.

1 bottle contains the active ingredient: cefuroxime sodium - 263 mg or 789 mg, which is 250 mg or 750 mg in terms of cefuroxime, respectively.

Solvent: water for injection.

1 tablet contains:

active substance: cefuroxime axetil - 300.72 mg or 601.44 mg, which in terms of cefuroxime is 250 mg or 500 mg, respectively;
auxiliary components: pregelatinized starch, sodium lauryl sulfate, crospovidone, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate;
composition of the film shell: Sepifilm LP 770 [microcrystalline cellulose (E460), hypromellose (methylhydroxypropyl cellulose) (E464), titanium dioxide (E171), stearic acid (E570)].

Pharmacological properties

Pharmacodynamics

The active ingredient of Axosef - cefuroxime - is an antibiotic of the second generation cephalosporin group, has a bactericidal effect. Shows activity against strains producing beta-lactamases and a wide range of other pathogens.

The mechanism of action of cefuroxime is due to its ability to bind to the main target proteins, which leads to the suppression of the synthesis of the bacterial cell wall.

Due to its good resistance to bacterial beta-lactamases, cefuroxime has a bactericidal effect on a wide range of ampicillin- and amoxicillin-resistant strains.

Treatment of severe infections is recommended taking into account the data on the local sensitivity of bacteria to cefuroxime. This is due to the ability of certain types of microorganisms to acquire resistance to cefuroxime over time, the prevalence of which may vary depending on the region.

In vitro activity of cefuroxime against the following microorganisms has been established:

gram-positive aerobes: strains of Staphylococcus aureus sensitive to methicillin (the sensitivity of bacteria is confirmed by the results of clinical studies), Streptococcus pyogenes (effectiveness has been demonstrated in clinical trials), coagulase-negative staphylococci (methicillin-sensitive strains), beta-hemolytic streptococci;
gram-negative aerobes: bacteria with proven clinical efficacy - Haemophilus influenzae (including ampicillin resistant strains), Moraxella catarrhalis, Haemophilus parainfluenzae, Neisseria gonorrhoeae (including penicillinase-producing and non-penicillinase-producing strains) (Neisseria spp.
gram-positive anaerobes: Propionibacterium spp., Peptostreptococcus spp.;
spirochetes: Borrelia burgdorferi (clinically proven efficacy).

Consideration should be given to the possibility of acquiring resistance to cefuroxime by the following bacteria:

gram-positive aerobes: Streptococcus pneumoniae (clinically proven efficacy), Viridans group streptococci;
gram-negative aerobes: Bordetella pertussis, Salmonella spp., Citrobacter spp. (excluding Citrobacter freundii), Providencia spp., Enterobacter spp. (excluding Enterobacter aerogenes, Enterobacter cloacae), Proteus spp. (excluding Proteus penneri, Proteus vulgaris), Proteus mirabilis, microorganisms with confirmed clinical efficacy - Escherichia coli, Klebsiella pneumoniae and other Klebsiella spp.;
gram-positive anaerobes: Clostridium spp. (except Clostridium difficile);
gram-negative anaerobes: Fusobacterium spp., Bacteroides spp. (excluding Bacteroides Fragilis).

The following bacteria are naturally resistant to cefuroxime:

gram-positive aerobes: Listeria monocytogenes, Enterococcus spp. (including Enterococcus faecalis, Enterococcus faecium);
gram-negative aerobes: Serratia spp., Burkholderia cepacia, Citrobacter freundii, Enterobacter cloacae, Enterobacter aerogenes, Proteus vulgaris, Proteus penneri, Stenotrophomonas maltophilia, Acinetobacter spp., Campylobacter spp., Morganella morppii. (including Pseudomonas aeruginosa);
gram-negative anaerobes: Bacteroides fragilis;
gram-positive anaerobes: Clostridium difficile;
others: Legionella spp., Mycoplasma spp., Chlamydia spp.

Pharmacokinetics

After i / m administration of the solution, the maximum concentration (Cmax) of cefuroxime in the blood plasma is reached after 0.5 hours or more.

After oral administration, absorption of cefuroxime axetil occurs in the gastrointestinal tract. Cefuroxime is released as a result of rapid hydrolysis in the mucous membrane of the small intestine and blood. Taking the film-coated tablet immediately after a meal ensures optimal absorption of cefuroxime axetil.

Plasma protein binding - 33-50%.

After the administration of cefuroxime sodium, the concentration of cefuroxime in bone tissue, synovial and intraocular fluids can reach a level exceeding the minimum inhibitory concentration for most microorganisms. With inflammation of the meninges of the brain, it crosses the blood-brain barrier.

Cefuroxime is not metabolized.

Excretion of the substance is carried out by glomerular filtration and tubular secretion.

After intramuscular or intravenous administration in adults, T _1/2 (half-life) of cefuroxime from serum is approximately 1 hour, in newborns, T _1/2 is from 3 to 5 hours.

T _1/2 when taking Axosef inside is 1-1.5 hours.

After parenteral administration, cefuroxime is excreted through the kidneys unchanged almost completely (85–90%) within 24 hours; in the first 6 hours it eliminates the bulk of the substance.

Concomitant therapy with probenecid causes an increase in cefuroxime excretion and a clinically significant increase in its serum Cmax.

With impaired renal function, there is an increase in T _{1/2 of} cefuroxime, which depends on the severity of the disease.

In patients on hemodialysis, serum cefuroxime concentrations are reduced. Within 4 hours of the session, approximately 60% of the dose taken is subject to removal, therefore, after the completion of the hemodialysis procedure, an additional single dose of cefuroxime should be administered.

Indications for use

The use of Axosef is indicated for the treatment of the following diseases that are caused by microorganisms sensitive to cefuroxime or in cases where the pathogen has not yet been identified:

ENT infections, including otitis media, pharyngitis, sinusitis, tonsillitis;
lower respiratory tract infections, including acute bacterial bronchitis, exacerbation of chronic bronchitis, bacterial pneumonia, lung abscess, infected bronchiectasis, postoperative chest diseases of infectious origin;
urinary tract infections, including cystitis, acute and chronic pyelonephritis, asymptomatic bacteriuria, acute uncomplicated urethritis, etc.;
dermatological infections such as cellulitis, infected wounds, furunculosis, pyoderma, impetigo, erysipelas;
gonorrhea;
gynecological and obstetric infections, including pelvic inflammatory disease such as cervicitis.

Additional indications for the use of Axosef in the form of a solution:

bone and joint infections, including osteomyelitis, septic arthritis;
meningitis;
peritonitis, septicemia and other infections;
prevention of infectious complications during orthopedic operations, extensive surgical interventions with an increased risk of infectious complications - the esophagus, abdominal organs, small pelvis, heart, lungs, blood vessels.

If necessary, Axosef can be used using a stepwise method of therapy, involving the transition from parenteral administration of cefuroxime to oral administration, including in the treatment of pneumonia or exacerbations of chronic bronchitis.

Contraindications

The use of Axosef is contraindicated for the treatment of patients with established hypersensitivity to beta-lactam antibiotics (including penicillins, cephalosporin antibiotics, carbapenems).

In addition, pills should not be prescribed to children under the age of three.

It is recommended to use the drug with caution in case of impaired renal function, ulcerative colitis and other diseases of the gastrointestinal tract (including data in history), in the early stages of pregnancy, during breastfeeding.

In addition, caution should be exercised if necessary intramuscular or intravenous administration of Axosef in combination with loop diuretics and aminoglycosides, as well as in newborns (especially premature babies).

Axosef, instructions for use: method and dosage

Powder for preparation of solution for intravenous and intramuscular administration

A ready-made solution of cefuroxime is used by intravenous or intramuscular injection.

The solution should be prepared under aseptic conditions.

To prepare a solution for intramuscular administration, 1 ml of a solvent (water for injection) is added to a bottle with 250 mg of cefuroxime, with 750 mg - 3 ml. Then the bottle is gently shaken until a suspension is formed. With an intramuscular injection, no more than 750 mg of Axosef can be injected into one site, therefore, when prescribing 1500 mg, it is necessary to use two doses of 750 mg, which should be injected into different injection sites (for example, into each of the buttocks).

To prepare a solution for intravenous administration, 250 mg of cefuroxime should be dissolved in 2 ml of water for injection, 750 mg in 6 ml.

For intravenous infusion lasting up to 0.5 hours, use a solution containing 750 mg of cefuroxime and 25 ml of water for injection. It can be inserted into an infusion tube or directly into a vein.

Cefuroxime sodium is stable when mixed with the following:

0.9% sodium chloride solution, 5% dextrose solution, Ringer's solution, Hartman's solution: cefuroxime is compatible with the indicated fluids for intravenous administration, after mixing with them, it remains active for 24 hours at room temperature;
metronidazole: after mixing a solution of cefuroxime at a concentration of 750 mg per 6 ml of solvent and metronidazole (25 mg / 50 ml), the activity of each component is maintained for 24 hours at a storage temperature of 4 ° C or no more than 6 hours at a temperature above 25 ° C;
xylitol solution: after mixing the drug solution with 5% or 10% xylitol solution at a concentration of 5 mg / ml, the finished solution is suitable for use within 24 hours at a storage temperature above 25 ° C;
lidocaine hydrochloride: an aqueous solution that contains not more than 1% lidocaine hydrochloride;
heparin, potassium chloride: 10 U (unit of action) / ml and 50 U / ml heparin or 10 mEq / L and 40 mEq / L potassium chloride when mixed with 0.9% sodium chloride solution cefuroxime is active for 24 hours at room conditions temperature.

In addition, the activity of Axosef is preserved in the presence of sodium hydrocortisone phosphate in 5% dextrose solution and 0.9% sodium chloride solution.

Do not mix cefuroxime in the same syringe with antibiotics from the aminoglycoside group.

It is not recommended to use sodium bicarbonate solution 2.74% for dilution of the powder, due to the fact that it affects the color of the solution. If necessary, simultaneous use, Axosef solution is injected directly into the tube of the infusion system.

For most infections, Axosef solution is used in the following doses:

adults: 750 mg 3 times a day i / m or i / v. In severe infections, intravenous administration is indicated at a dose of 1500 mg 3 times a day. If necessary, the drug can be administered at intervals of 6 hours. Depending on the clinical indications, to achieve a therapeutic effect, the drug is prescribed in a dose of 750 mg or 1500 mg 2 times a day (i / m or i / v), followed by the transfer of the patient to taking Axosef in the form of tablets. The maximum daily dose is 6000 mg;
children: at the rate of 30-100 mg per 1 kg of the child's body weight per day. The received dose is divided into 3-4 injections. The optimal dose for most infections is 60 mg per kg per day;
newborns: 30-100 mg per 1 kg of body weight per day, divided into 2-3 injections.

Recommended dosage for the treatment of the following diseases and prevention of postoperative complications:

gonorrhea: adults - two doses of 750 mg IM (750 mg in each of the buttocks) once;
meningitis (as a basic therapy for bacterial meningitis caused by susceptible strains): adults - 3000 mg IV with an interval of 8 hours; children - at the rate of 150–250 mg per 1 kg of the child's body weight per day, the dose received is divided into 3–4 intravenous administration; newborns - 100 mg per 1 kg of body weight per day, iv;
prevention of complications during operations on the abdominal cavity, pelvis or orthopedic interventions in adult patients: intravenous during induction of anesthesia - 1500 mg once. Additionally, 8 hours after the operation, intramuscular administration of 750 mg of Axosef is possible, then after 16 hours - 750 mg;
prevention of complications during surgery on the heart, blood vessels, lungs or esophagus in adult patients: IV during induction of anesthesia - 1500 mg. Within 24–48 hours after the operation, intramuscular administration of the drug in a dose of 750 mg 3 times a day is indicated;
pneumonia: adults - 1500 mg 2-3 times a day (IV or IM) for 2-3 days. Then the patient is transferred to the oral form of Axosef at a dose of 500 mg 2 times a day for 7-10 days;
exacerbation of chronic bronchitis: 750 mg 2-3 times a day (IV or IM) for 2-3 days. Then it is shown taking the drug in the form of tablets at a dose of 500 mg 2 times a day for 5-10 days.

When carrying out endoprosthetics of joints, Axosef in the form of a dry powder at a dose of 1500 mg of cefuroxime can be added to the contents of the bags with methyl methacrylate cement polymer before mixing with liquid monomer.

With stepwise antibacterial therapy, the duration of parenteral and oral administration of Axosef is determined individually, depending on the patient's clinical condition, the severity of the infection, and the sensitivity of the pathogen. In the absence of a therapeutic effect 3 days after the start of treatment, the parenteral course of therapy should be continued.

In case of severe renal dysfunction, correction of the dosage regimen is required, which is performed taking into account QC:

CC more than 20 ml / min: 750-1500 mg 3 times a day;
CC 10–20 ml / min: 750 mg 2 times a day;
CC less than 10 ml / min: 750 mg once a day.

Patients on hemodialysis, after completing the hemodialysis session, must additionally enter 750 mg of the drug (i / v or i / m).

For peritoneal dialysis, Axosef can be added to dialysis solution at a dose of 250 mg for every 2 liters as an adjunct to parenteral administration.

When using continuous hemodialysis with high-speed hemofiltration or using an arteriovenous shunt, patients with renal insufficiency should be prescribed Axosef at a dose of 750 mg 2 times a day.

During the use of hemofiltration at a low rate, the dose is indicated taking into account the CC.

With clinical indications that allow the transition from parenteral administration of cefuroxime to oral administration, the patient can be transferred to treatment with the drug in the form of tablets.

Film-coated tablets

Axosef tablets are taken orally, swallowed whole, after meals.

Violation of the integrity of the film shell of the tablet should not be allowed.

The duration of a standard course of therapy is 7 days, but taking into account clinical indications and the patient's condition, it can be from 5 to 10 days.

The parenteral and oral form of cefuroxime allows the use of stepwise antibiotic therapy, which involves a sequential transition from intramuscular or intravenous administration of the drug to treatment with tablets. The doctor determines the duration of the parenteral and oral course of treatment, taking into account the severity of the infection and the clinical picture.

Recommended dosage of Axosef for adult patients:

most infections: 250 mg 2 times a day;
pyelonephritis: 250 mg 2 times a day;
bronchitis and other infections of the lower respiratory tract of mild to moderate severity: 250 mg 2 times a day;
suspected pneumonia, severe lower respiratory tract infections: 500 mg 2 times a day;
uncomplicated gonorrhea: 1000 mg once;
borreliosis or Lyme disease (including children over 12 years of age): Axosef 500 mg 2 times a day for 20 days;
pneumonia (stepwise therapy): intravenous or intramuscular administration of a solution of cefuroxime in the form of sodium salt - 1500 mg 2-3 times a day for 2-3 days, then the patient is transferred to the drug in the form of tablets - 500 mg 2 times a day for 7-10 days;
exacerbation of chronic bronchitis (stepwise therapy): intravenous or intramuscular injection of cefuroxime solution in the form of sodium salt - 750 mg 2-3 times a day for 2-3 days, then the patient is transferred to Axosef tablets 500 mg 2 times day for 5-10 days.

For the treatment of otitis media or more severe infections in children over the age of three years, 250 mg is prescribed 2 times a day. The maximum daily dose for children is 500 mg.

In case of impaired renal function, the dose of Axosef is adjusted taking into account the QC indicator:

QC 30 ml / min and above: dose adjustment is not required;
CC 10–29 ml / min: a standard single dose is prescribed once a day;
CC is less than 10 ml / min: a standard single dose is prescribed once every 2 days.

Patients on hemodialysis should additionally take one standard single dose after each session.

Side effects

Against the background of intramuscular and intravenous administration of Axosef solution, the following undesirable reactions may occur:

infectious and parasitic diseases: rarely - candidiasis of the mucous membranes (including the oral cavity);
from the lymphatic system and blood: often - eosinophilia, neutropenia; infrequently - a decrease in hemoglobin levels, leukopenia, positive Coombs' test; rarely, thrombocytopenia; very rarely - hemolytic anemia;
from the immune system: infrequently - skin rash, itching, urticaria; rarely, drug fever; very rarely - cutaneous vasculitis, interstitial nephritis, anaphylaxis;
from the gastrointestinal tract: infrequently - gastrointestinal upset; very rarely - pseudomembranous colitis;
on the part of the hepatobiliary system: often - a transient increase in the activity of hepatic enzymes; infrequently - a transient increase in the concentration of bilirubin;
dermatological reactions: very rarely - erythema multiforme, toxic epidermal necrolysis, Stevens-Johnson syndrome;
on the part of the kidneys and urinary tract: very rarely - an increase in the content of residual nitrogen in the blood, an increase in the level of serum creatinine, a decrease in creatinine clearance;
on the part of the organ of hearing and labyrinth disorders: very rarely - in the treatment of meningitis in children, there is a mild or moderate degree of hearing loss;
local reactions: often - soreness at the injection site and other reactions, including thrombophlebitis.

Against the background of the use of Axosef tablets, the following undesirable effects may occur:

infectious and parasitic diseases: often - overgrowth of Candida fungi;
from the lymphatic system and blood: often - eosinophilia; infrequently - thrombocytopenia, positive Coombs' test, leukopenia (including severe); very rarely - hemolytic anemia;
from the nervous system: often - dizziness, headache;
from the gastrointestinal tract: often - abdominal pain, diarrhea, nausea and other gastrointestinal disorders; infrequently - vomiting; rarely - pseudomembranous colitis;
from the hepatobiliary system: often - a transient increase in the activity of alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase; very rarely - jaundice (often cholestatic), hepatitis;
from the immune system: infrequently - skin rash; rarely - itchy skin, urticaria; very rarely - serum sickness, drug fever, anaphylaxis;
dermatological reactions: very rarely - erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (exanthematous necrolysis).

Overdose

Symptoms: seizures as a result of excitation of the central nervous system.

Treatment: the appointment of antiepileptic drugs. For accelerated elimination of cefuroxime, it is advisable to use hemodialysis or peritoneal dialysis. Careful monitoring of vital body functions is required, if necessary, the appointment of supportive therapy.

special instructions

If Axosef is required in combination with strong diuretics (including furosemide, aminoglycosides), especially with a history of kidney disease or in old age, it is important to closely monitor renal function.

Against the background of cefuroxime therapy, the growth of fungi of the genus Candida may occur, and prolonged use of the antibiotic increases the risk of overgrowth of other insensitive bacteria (including Clostridium difficile and enterococci), in some cases this is the reason for stopping treatment.

In patients with Lyme disease while taking Axosef tablets, the Jarish-Herxheimer reaction may appear, due to the bactericidal activity of cefuroxime axetil against the causative agent of the disease of the spirochete Borrelia burgdorferi. For this disease, the onset of symptoms is a characteristic consequence of the use of antibiotics.

Given the risk of pseudomembranous colitis of varying severity against the background of antibiotic therapy, including a life-threatening patient, with the appearance of prolonged diarrhea of a pronounced nature and abdominal cramps, treatment should be stopped immediately and the patient should be examined accordingly. During this period, you can not take drugs that inhibit intestinal peristalsis.

Axosef does not affect the results of studies on the determination of glucose in urine using enzymatic methods. There may be interactions when using Benedict, Fading, or KleeneTest, but this does not lead to false positives.

It is recommended to use the glucose oxidase or hexokinase method for measuring glucose in blood or plasma. Carrying out a ferricyanide sugar test can give a false negative result. Axosef does not change the study results when using the alkaline-picrate method to determine the level of creatinine.

Influence on the ability to drive vehicles and complex mechanisms

The use of Axosef does not affect the patient's ability to drive vehicles or complex mechanisms.

Application during pregnancy and lactation

The use of Axosef during gestation is indicated in cases where the expected therapeutic effect for the mother exceeds the potential threat to the fetus and child.

When prescribing the drug to nursing mothers, the excretion of cefuroxime in breast milk should be taken into account and the necessary precautions should be taken.

Pediatric use

The use of Axosef tablets for the treatment of children under three years of age is contraindicated.

Caution should be used in / m or / in the introduction of the drug in newborns (especially premature babies).

With impaired renal function

It is recommended to prescribe Axosef with caution to patients with impaired renal function.

Powder for preparation of solution for intravenous and intramuscular administration

In case of severe renal dysfunction, the dosage regimen is adjusted taking into account the CC indicator:

CC more than 20 ml / min: 750-1500 mg 3 times a day;
CC 10–20 ml / min: 750 mg 2 times a day;
CC less than 10 ml / min: 750 mg once a day.

Patients on hemodialysis, after the end of the session, must additionally enter 750 mg of cefuroxime sodium (i / v or i / m).

During peritoneal dialysis, Axosef can be added to the dialysis solution at a dose of 250 mg for every 2 liters as an adjunct to parenteral administration.

When using continuous hemodialysis with high-speed hemofiltration or using an arteriovenous shunt, patients with renal insufficiency should be prescribed intravenous or intramuscular administration of the drug at a dose of 750 mg 2 times a day.

In the case of using hemofiltration at a low rate, the appointment of a dose of cefuroxime sodium solution is indicated, taking into account CC.

Film-coated tablets

In case of impaired renal function, the dose of Axosef tablets is adjusted taking into account the QC indicator:

QC 30 ml / min and above: dose adjustment is not required;
CC 10–29 ml / min: a standard single dose is prescribed once a day;
CC is less than 10 ml / min: a standard single dose is prescribed once every 2 days.

Patients on hemodialysis should additionally take one standard single dose of cefuroxime axetil after each session.

Drug interactions

With the simultaneous use of Axosef:

loop diuretics (furosemide), aminoglycosides: taking strong diuretics increases the risk of nephrotoxic effects associated with slowing tubular secretion, decreased renal clearance, increased half-life of cefuroxime, which leads to an increase in its concentration in plasma. When combined with aminoglycosides, an additive effect occurs, synergism of action is possible. Mixing cefuroxime sodium with aminoglycosides in one syringe is contraindicated;
oral hormonal contraceptives: reduced reabsorption of estrogen, which can lead to a decrease in the effectiveness of oral hormonal contraceptives;
drugs that reduce the acidity of gastric juice: it should be borne in mind that lowering the acidity of gastric juice reduces the bioavailability of cefuroxime axetil and levels the effect of its increased absorption after meals.

Analogs

Axosef's analogs are Acenoveriz, Cefuroxime, Cefuroxime Kabi, Antibioxime, Super, Zinnat, Aksetin, Cefurotek, Cefurus, Cefurozin, Cefurabol, Xorim, Zinacef, Cefroxim J, Cetyl Lupine, etc.

Terms and conditions of storage

Keep out of the reach of children.

Store at temperatures up to 25 ° C, powder - protected from moisture and light.

Shelf life: powder and tablets - 3 years; solvent - 5 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Axosef

Reviews about Axosef on specialized sites are quite rare. Patients most often indicate the development of undesirable actions, including from the gastrointestinal tract.

Price for Axosef in pharmacies

The price for Axosef can be:

tablets 250 mg: 10 pcs. - from 188 rubles., 14 pcs. - from 231 rubles;
tablets 500 mg: 10 pcs. - from 324 rubles., 14 pcs. - from 443 rubles;
powder for preparation of a solution for intravenous and intramuscular administration of 750 mg: 1 bottle - from 98 rubles.

Axosef: prices in online pharmacies

Drug name

Price

Pharmacy

Axosef 750 mg powder for the preparation of a solution for intravenous and intramuscular administration, complete with a solvent 1 pc.

119 RUB

Buy

Axosef 250 mg film-coated tablets 10 pcs.

219 r

Buy

Axosef 500 mg film-coated tablets 10 pcs.

412 RUB

Buy

Anna Kozlova Medical journalist About the author

Education: Rostov State Medical University, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!